Magnesium Threonate Cognition Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Threonate Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Additionally, the decline in magnesium concentrations in modern food crops may contribute to reduced dietary magnesium intake, potentially increasing the risk of magnesium deficiency and chronic health conditions, such as cardiovascular disease and metabolic syndrome. [Lopresti Adrian L. (2026); evidence level 2]
• Moreover, lower blood concentrations of magnesium have been identified in adults with reduced cognitive performance, mild cognitive impairment, and Alzheimer's disease. [Lopresti Adrian L. (2026); evidence level 2]
• Epidemiological and clinical studies suggest that magnesium deficiency may be associated with the onset and progression of these conditions, whereas adequate magnesium supplementation may exert a protective effect. [Varga Péter (2025); evidence level 3]
• In addition to these mechanisms, depression itself is a well-established risk factor for accelerated cognitive decline and the development of dementia, including both Alzheimer's disease and vascular cognitive impairments, likely mediated through chronic inflammation, HPA axis dysregulation, and reduced hippocampal neurogenesis. [Varga Péter (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For magnesium threonate cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lopresti Adrian L. (2026). The effects of magnesium L-threonate (Magtein ® ) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. DOI: 10.3389/fnut.2025.1729164. PMCID: PMC12832366. PMID: 41601871. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12832366/
• Varga Péter (2025). The Role of Magnesium in Depression, Migraine, Alzheimer’s Disease, and Cognitive Health: A Comprehensive Review. DOI: 10.3390/nu17132216. PMCID: PMC12252419. PMID: 40647320. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12252419/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.